157 related articles for article (PubMed ID: 32080226)
1. ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab.
Agnolon V; Contato A; Meneghello A; Tagliabue E; Toffoli G; Gion M; Polo F; Fabricio ASC
Sci Rep; 2020 Feb; 10(1):3016. PubMed ID: 32080226
[TBL] [Abstract][Full Text] [Related]
2. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
3. Preparation and application of immunoaffinity in-tube solid phase microextraction column with oriented antibody-immobilized porous layer open tubular capillary for high sensitive quantification of serum extracellular domain of human epidermal growth factor receptor 2 levels.
Pan J; Song Y; Xu B; Liu J; Fu L; Xu L
J Chromatogr A; 2020 May; 1619():460974. PubMed ID: 32087879
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
5. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Fornier MN; Seidman AD; Schwartz MK; Ghani F; Thiel R; Norton L; Hudis C
Ann Oncol; 2005 Feb; 16(2):234-9. PubMed ID: 15668276
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.
Deng X; Zheng X; Yang H; Moreira JM; Brünner N; Christensen H
PLoS One; 2014; 9(9):e106448. PubMed ID: 25192037
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients.
Gauchez AS; Ravanel N; Villemain D; Brand FX; Pasquier D; Payan R; Mousseau M
Anticancer Res; 2008; 28(5B):3067-73. PubMed ID: 19031958
[TBL] [Abstract][Full Text] [Related]
9. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
Köstler WJ; Schwab B; Singer CF; Neumann R; Rücklinger E; Brodowicz T; Tomek S; Niedermayr M; Hejna M; Steger GG; Krainer M; Wiltschke C; Zielinski CC
Clin Cancer Res; 2004 Mar; 10(5):1618-24. PubMed ID: 15014012
[TBL] [Abstract][Full Text] [Related]
11. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
14. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
[TBL] [Abstract][Full Text] [Related]
15. The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.
Antos A; Topolska-Woś A; Woś M; Mitura A; Sarzyńska P; Lipiński T; Kurylcio A; Ziółkowski P; Świtalska M; Tkaczuk-Włach J; Gamian A; Polkowski WP; Staniszewska M
Sci Rep; 2024 Feb; 14(1):3978. PubMed ID: 38368450
[TBL] [Abstract][Full Text] [Related]
16. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
17. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
[TBL] [Abstract][Full Text] [Related]
18. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.
Jamieson D; Cresti N; Verrill MW; Boddy AV
J Immunol Methods; 2009 Jun; 345(1-2):106-11. PubMed ID: 19376123
[TBL] [Abstract][Full Text] [Related]
20. p185 HER2/neu epitope mapping with murine monoclonal antibodies.
Centis F; Tagliabue E; Uppugunduri S; Pellegrini R; Martignone S; Mastroianni A; Ménard S; Colnaghi MI
Hybridoma; 1992 Jun; 11(3):267-76. PubMed ID: 1379973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
